| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-47 |
Sentence |
denotes |
RET inhibition: implications in cancer therapy. |
| T1 |
0-47 |
Sentence |
denotes |
RET inhibition: implications in cancer therapy. |
| TextSentencer_T2 |
48-61 |
Sentence |
denotes |
INTRODUCTION: |
| T2 |
48-61 |
Sentence |
denotes |
INTRODUCTION: |
| TextSentencer_T3 |
62-177 |
Sentence |
denotes |
The RET gene encodes a receptor tyrosine kinase essential for ontogenesis of the enteric nervous system and kidney. |
| T3 |
62-177 |
Sentence |
denotes |
The RET gene encodes a receptor tyrosine kinase essential for ontogenesis of the enteric nervous system and kidney. |
| TextSentencer_T4 |
178-358 |
Sentence |
denotes |
Following identification of RET, it was found that somatic rearrangements of this gene, conventionally designated as RET/PTC, are frequently present in papillary thyroid carcinoma. |
| T4 |
178-358 |
Sentence |
denotes |
Following identification of RET, it was found that somatic rearrangements of this gene, conventionally designated as RET/PTC, are frequently present in papillary thyroid carcinoma. |
| TextSentencer_T5 |
359-533 |
Sentence |
denotes |
Subsequently, activating germ line point mutations of RET were identified as being responsible for the hereditary medullary thyroid carcinoma syndromes MEN2A, MEN2B and FMTC. |
| T5 |
359-533 |
Sentence |
denotes |
Subsequently, activating germ line point mutations of RET were identified as being responsible for the hereditary medullary thyroid carcinoma syndromes MEN2A, MEN2B and FMTC. |
| TextSentencer_T6 |
534-627 |
Sentence |
denotes |
RET rearrangements have recently been identified in a small fraction of lung adenocarcinomas. |
| T6 |
534-627 |
Sentence |
denotes |
RET rearrangements have recently been identified in a small fraction of lung adenocarcinomas. |
| TextSentencer_T7 |
628-641 |
Sentence |
denotes |
AREA COVERED: |
| T7 |
628-641 |
Sentence |
denotes |
AREA COVERED: |
| TextSentencer_T8 |
642-874 |
Sentence |
denotes |
The authors review the current field concerning the RET gene and protein, its involvement in cancer and the preclinical and clinical studies which highlight its role as a potentially important therapeutic target for several cancers. |
| T8 |
642-874 |
Sentence |
denotes |
The authors review the current field concerning the RET gene and protein, its involvement in cancer and the preclinical and clinical studies which highlight its role as a potentially important therapeutic target for several cancers. |
| TextSentencer_T9 |
875-890 |
Sentence |
denotes |
EXPERT OPINION: |
| T9 |
875-890 |
Sentence |
denotes |
EXPERT OPINION: |
| TextSentencer_T10 |
891-1037 |
Sentence |
denotes |
Many multitargeted inhibitors which crossreact with RET have been developed and investigated in clinical trials targeting many cancer indications. |
| T10 |
891-1037 |
Sentence |
denotes |
Many multitargeted inhibitors which crossreact with RET have been developed and investigated in clinical trials targeting many cancer indications. |
| TextSentencer_T11 |
1038-1173 |
Sentence |
denotes |
In particular, VEGFR/PDGFR inhibitors, widely explored as antiangiogenics, have been intensively studied in thyroid carcinoma patients. |
| T11 |
1038-1173 |
Sentence |
denotes |
In particular, VEGFR/PDGFR inhibitors, widely explored as antiangiogenics, have been intensively studied in thyroid carcinoma patients. |
| TextSentencer_T12 |
1174-1384 |
Sentence |
denotes |
Notwithstanding the efficacy observed with such agents, their common clinical activity in thyroid carcinoma is of short duration and includes frequent and severe side effects, limiting their therapeutic action. |
| T12 |
1174-1384 |
Sentence |
denotes |
Notwithstanding the efficacy observed with such agents, their common clinical activity in thyroid carcinoma is of short duration and includes frequent and severe side effects, limiting their therapeutic action. |
| TextSentencer_T13 |
1385-1490 |
Sentence |
denotes |
These findings are discussed and the need for improved, more specific RET-targeting drugs is highlighted. |
| T13 |
1385-1490 |
Sentence |
denotes |
These findings are discussed and the need for improved, more specific RET-targeting drugs is highlighted. |